Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
E. P. Kusnadi, A. S. Trigos, C. Cullinane, D. L. Goode, O. S. Larsson, J. R. Devlin, K. T. Chan, D. P. DeSouza, M. J. McConville, G. A. McArthur, G. Thomas, E. Sanij, G. Poortinga, R. D. Hannan, K. M. Hannan, , R. B. Pearson
The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.
bioRxiv · Mar 26, 2020Cancer Biology